Akèy › Kansè pankreyas › Tennessee › Nashville
Etid klinik pou Kansè pankreyas nan Nashville, TN
39 etid pou Kansè pankreyas ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Ap rekriteFaz 3
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology, Nashville
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
- Tennessee Oncology PLLC, Nashville
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ap rekriteFaz 2
- SCRI Oncology Partners, Nashville
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- SCRI Oncology Partners, Nashville
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute - Pharmacy, Nashville
- SCRI Oncology Partners, Nashville
A Study of PHN-012 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- PHN-012-001 Site, Nashville
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
DESTINY-PANTUMOUR04
Ap rekriteEtid obsèvasyon
- Research Site, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Vanderbilt University Medical Center, Nashville
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Ap rekriteFaz 2/3
- Henry-Joyce Cancer Clinic, Nashville
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Ap rekriteFaz 3
- SCRI Oncology Partners, Nashville
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Ap rekriteFaz 3
- Investigative Site US039, Nashville
- Investigative Site US060, Nashville
- Investigative Site US070, Nashville
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Ap rekriteFaz 1/2
- SCRI Oncology Partners, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institue, Nashville
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Ap rekriteFaz 1/2
- Tennessee Oncology, PLLC, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Center, Nashville
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Ap rekriteEtid obsèvasyon
- Vanderbilt University/Ingram Cancer Center, Nashville
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Ap rekriteFaz 2
- Sarah Cannon Research Institute, Nashville
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Ap rekriteFaz 1
- Vanderbilt - Ingram Cancer Center, Nashville
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Investigative Site #102, Nashville
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
Ap rekriteFaz 2
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Ap rekriteFaz 2
- SCRI Oncology Partners, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Ap rekriteFaz 1
- Sarah Cannon, SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Nashville
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- SCRI Oncology Partners, Nashville
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
Ap rekriteEtid obsèvasyon
- Veterans Affairs Medical Center - Nashville, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response
Ap rekrite
- Vanderbilt University Medical Center, Nashville
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Ap rekriteFaz 2
- Ohio State University-Telemedicine, Nashville
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Tennessee Oncology, Nashville
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #6, Nashville
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Ap rekriteFaz 1
- Vanderbilt University Medical Center, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Ap rekriteFaz 1/2
- SCRI Oncology Partners, Nashville
Etid Kansè pankreyas nan lòt vil
- Houston, TX61 etid
- New York City, NY60 etid
- Boston, MA43 etid
- Los Angeles, CA35 etid
- St. Louis, MO33 etid
- Arlington, VA33 etid
- Baltimore, MD31 etid
- San Antonio, TX31 etid
- Philadelphia, PA26 etid
- Tampa, FL26 etid
- Durham, NC24 etid
- San Diego, CA24 etid
Lòt etid nan Nashville
- Kansè Poumon ki pa ti selil97 etid
- Kansè nan tete81 etid
- Kansè Metastatik70 etid
- Kansè kolorektal69 etid
- Kansè (tout kalite)65 etid
- Kansè ovè49 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Karsinòm selil skuamèz tèt ak kou39 etid
- Kansè Endomèt38 etid
- Melanom33 etid
- Myelom Miltip32 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.